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Introduction. The use of unlicensed food and herbal supplements to enhance sexual functions is drastically increasing. This
phenomenon, combined with the availability of these products over the Internet, represents a challenge from a clinical and a
public health perspective. Methods. A comprehensive multilingual assessment of websites, drug fora, and other online resources
was carried out between February and July 2013 with exploratory qualitative searches including 203 websites. Additional searches
were conducted using the Global Public Health Intelligence Network (GPHIN). Once the active constitutes of the products
were identified, a comprehensive literature search was carried out using PsycInfo and PubMed. Results. The most common
sexual enhancement products available on the Internet were identified. Their active ingredients included yohimbine, maca, horny
goat weed and Ginkgo biloba. These four substances were reported with the occurrence of adverse events and the induction
of psychological symptoms, such as mood changes, anxiety, and hallucinations as well as addictive behaviours. Conclusions.
Uncontrolled availability of sexual enhancement products that contain potentially harmful substances is a major public health
concern.The possible impact on population health, particularly among subjects with psychiatric disorders, usually at risk for sexual
dysfunction, may be significant. This new trend needs to be extensively studied and monitored.
1. Introduction
The use of food and herbal supplements to enhance erectile
function as well as sexual arousal and desire has become
increasingly popular in the recent years [1, 2].These products
are advertised on the Internet as “natural” and “safer” alter-
natives to pharmaceutical products, such as gold standard for
treatment of erectile dysfunction and the phosphodiesterase
type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, and varde-
nafil). However, they often contain potent active constituents
[3–5], which remain undeclared on the packaging [6, 7].
The effects of the aforementioned products, thus, remain
unknown until reports on harms expose the problem and
accurate clinical evaluation takes place.
Since herbal supplements are plant products, they are
generally perceived and hence marketed as natural and,
therefore, “safe” [8]. However, several case reports of side
effects to herbs and herbal products have been reported
[8, 9], such as on- and off-target effects from biologically
active ingredients, side effects caused by contaminants, and
herb-drug interactions. It is difficult to determine the true
frequency of side effects from herbs and herbal products,
since surveillance systems are much less extensive than those
in place for pharmaceutical drugs. It is estimated that less
than 1% of side effects or adverse events for herbal products
are recorded with the current surveillance systems [10].
Some of the side effects and adverse events due to
ingestion of herbs and herbal products are related to their
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action on central nervous system and can present as mood
alterations, anxiety, mania, depression, hallucinations, and
addictive behaviour; one example of such herbal product is
ephedra, which was banned in the USA in 2004 [11].
However, psychological safety profiles of sexual enhance-
ment products have not been characterised. This review,
therefore, aimed at identifying the sexual enhancement prod-
ucts advertised and sold on the Internet while collecting
information about their characteristics (i.e., brand names,
costs, ingredients, availability, declared advantages, and dis-
advantages). We then focused on four substances, which are
common in these products: yohimbine, maca, horny goat
weed, and Ginkgo biloba, as these were reported to induce
psychological side effects. We also described, less in detail,
other components of sexual enhancer products thatmay have
both somatic and psychological side effects.
2. Methods
A multilingual qualitative assessment of a range of websites,
drug fora, and other online resources (i.e., e-commerce, e-
newsgroups, chat rooms, videos, e-newsletters, and bulletin
boards)was carried out between February 2012 andMay 2013.
Exploratory qualitative searches of 203 websites in English
and Italian took place using brand names through Google
search engine. Of these, 106 were considered to be relevant
for the study and as such were monitored on a regular basis,
that is daily (𝑛 = 21), weekly (𝑛 = 32), or monthly (𝑛 =
53), depending on their relevance.The remaining 97 websites
were considered not to bear any interest for the present
study and thus were no longer monitored. Further specific
searches in the database provided by The Global Public
Health Intelligence Network (GPHIN) also took place. This
is a secure Internet-based early warning system that gathers
preliminary reports of public health significance by mon-
itoring global media sources near “real-time,” 24 hours a
day, 7 days a week basis. GPHIN is operated by the Public
Health Agency of Canada and monitors news sources and
websites across the globe in 9 languages (e.g., English, French,
Farsi, Portuguese, Arabic, Russian, Spanish, and Chinese
simplified/traditional) [12]. While a series of algorithms were
used and adjusted to capture relevant information, analysis
of relevant data since 2003 was also carried out manually by
amultidisciplinary andmultilingual team of analysts. Finally,
once the active constituents of these products were identified,
a comprehensive literature search was carried out using
PsycInfo and Pubmed databases. Permission for the study
was granted by the School of Pharmacy Ethics Committee,
Hatfield, UK (15 December, 2010; PHAEC/10-42).
3. Results
During the website assessment stage where 136 websites
were monitored for 6 months, we have identified 15 sexual
enhancement products advertised and sold on the Internet.
The characteristics of these products are summarized in
Table 1. Yohimbe, ginseng, Ginkgo biloba, maca, horny goat
weed, and L-arginine were claimed to be the most common
ingredients in those products. Among all the substances
identified in these products, we have found psychological
safety concerns for only four: yohimbine, maca, horny goat
weed, and Ginkgo biloba. Biological, pharmacological, and
safety profiles of these four substances are presented below.
3.1. Yohimbine
3.1.1. Source and Preparations. Yohimbine is a natural
tryptamine alkaloid, which can be extracted from the bark
of a variety of plants mostly of African and Asian origin
such as Pausinystalia yohimbe (also known as yohimbe tree)
and the root of Rauvolfia serpentina. Yohimbe bark extract
is traditionally used in Africa as an aphrodisiac: it has to be
underlined, though, that tree bark does contain a large num-
ber of alkaloids, and yohimbine level in this natural source
may be low. Yohimbine concentration has been suggested to
increase in older branches [13]. A 1995 study by Betz et al. on
dietary supplements containing Yohimbe extracts has shown
that the yohimbine content may range from < 0.1 to 489 ppm
comparedwith 7089 ppm in the authenticmaterial, which has
been attributed to the intense dilution of final product [14].
Currently, yohimbine-containing products are advertised on
the Internet not only for treating erectile dysfunction and
enhancing sexual performance, but also as a fast weight-loss
and body-building supplement [15–17]. Brand names include
“The Millennium Male Horse Power Capsule” [18], Syntrax
[15], and Xytomax (see Table 1).
3.1.2. Mechanism of Action. Yohimbine has high affinity to
human alpha-2 adrenoceptors, moderate affinity to alpha-
1 adrenoceptors, and low affinity to some of the serotonin
and dopamine receptors in the central and peripheral ner-
vous systems [19]. Alpha-2 adrenoceptors mediate erection-
inhibiting impulses in the central nervous system. Yohimbine
is generally believed to enhance central sexual impulse by
blocking the alpha-2 adrenoceptors in the locus coeruleus
in the brain [20]. In the periphery, yohimbine has been
suggested to inhibit alpha-1 and alpha-2 adrenoceptors aswell
as enhancing the release of nitric oxide (NO) from cavernosal
endothelial cells [21, 22]. In conclusion, the mechanism of
action of yohimbine in enhancing sexual function is currently
unclear.
3.1.3. Pharmacokinetics. Yohimbine hydrochloride is rapidly
absorbed and the maximum plasma concentration is gener-
ally achieved in less than one hour after oral administration
[23, 24]. The mean bioavailability is low and is subject to
very high variation from one individual to another [25].
The plasma concentration of yohimbine does not appear to
correlate with the dose of the compound administered [26].
3.1.4. Efficacy. Ameta-analysis in 1998 of seven clinical trials
with yohimbine has shown a superiority of the compound
over placebo in treatment of erectile dysfunction [27]. Yohim-
bine has also been reported to be effective in treatment of
orgasmic disorders such as delayed ejaculation [28]. There
have been no clinical studies testing Yohimbe bark.TheClini-
cal Guidelines Panel on Erectile Dysfunction of theAmerican
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Urological Association (AUA) has concluded that the data
available on Yohimbine do not allow it to be recommended
as standard treatment in erectile dysfunction particularly not
in organic aetiology [29]. International Society for Sexual
Medicine (ISSM) Standards Committee has recently stated
“if yohimbine has any potential indications for use in ED
management, it would be among nonorganic ED; apart from
ED, yohimbine has shown a limited efficacy in the treatment of
premature ejaculation” [21].
3.1.5. Safety. The side effects of yohimbine include high
blood pressure, increased heart rate, manic reactions, bron-
chospasm, palpitations, insomnia, anxiety, irritability, shiver-
ing, sweating, nausea, flushing, and headaches which all can
be attributed to its central adrenergic activity [26, 30].
3.1.6. Case Reports Concerning Safety of Yohimbine. Adverse
events mostly due to self-administration of yohimbine have
been reported since 1980s. In 1993, Sandler andAronson have
described the development of progressive renal failure, cuta-
neous eruption, and a lupus-like syndrome in a 42-year-old
Afro-Americanman following yohimbine use [31]. Myers has
reported a case of refractory priapism in a 42-year-old HIV
infected and depressedman who self-administered a product
containing yohimbine to treat his erectile dysfunction and
was subsequently admitted to emergency department with
a 20-hour lasting erection which required insertion of a
proximal corpus cavernosum to spongiosum shunt (Quackles
shunt) [32]. According to California Poison Control System,
238 cases of adverse reactions after yohimbine consump-
tion have been identified within a 7-year period (2000–
2006): most commonly reported adverse events have been
gastrointestinal distress, tachycardia, anxiety, agitation, and
hypertension [33]. US National Institute of Health also warns
consumers about taking yohimbine supplements if they suffer
from schizophrenia, anxiety, depression, or posttraumatic
stress disorder [34]. Additional situation of emergency has
been reported in Ammanwhere the public corporation of the
food and the medicine warned the citizens about the use of
some unlicensed sexual stimulants, such as yohimbine, for
its inclusion of poisonous substance strychnine that caused
convulsions, hallucinations, and heart and kidney failure [35].
More recently, Yohimbine was detected in a product labelled
as OxyELITE Pro and sold online as slimming pills. This
caused the hospitalisation of two female patients aged 34 and
21 inHongKong for acute hepatitis symptoms. As a result, the
Department of Health opened an investigation and appealed
to members of the public not to buy or consume the product
[30].
3.1.7. Psychological Safety. As mentioned above, anxiety and
agitation are among the most common side effects of yohim-
bine or yohimbine-containing products [33]. US National
Institute of Health warns consumers about taking yohimbine
or Yohimbe supplements with some of the antidepressants
and antipsychosis drugs: “People should not combine Yohimbe
with monoamine oxidase (MAO) inhibitors as effects may be
additive. Yohimbe should be usedwith cautionwhen takenwith
medicines for high blood pressure, tricyclic antidepressants, or
phenothiazines (a group of medicines used mostly for mental
health conditions such as schizophrenia). People with kidney
problems and people with psychiatric conditions should not use
Yohimbe” [34]. In 1985, Linden et al. have reported a case
of a 16-year-old girl who experienced an acute dissociative
reaction accompanied by weakness, paraesthesia, incoordi-
nation, anxiety, headache, and chest pain after the ingestion
of an aphrodisiac called “yo-yo,” which has been later iden-
tified as yohimbine [36]. Acute neurotoxic effects related to
the ingestion of yohimbine-containing products have been
reported byGiampreti et al., whohas reported the case of a 37-
year-old bodybuilder presented with malaise, vomiting, loss
of consciousness, and repeated seizures after ingestion of 5 g
of yohimbine during a competition [37].
3.2. Maca
3.2.1. Source and Preparations. Maca (Lepidium meyenii) is
a Peruvian plant, which belongs to the Brassicaceae family.
It grows in central Andes at more than 4000m altitude; it
is constituted of a flat overground portion and underground
hypocotyl and roots. Hypocotyl colour allows the distinction
of three different varieties: white, yellow, and black maca.
Naturally dried hypocotyls have been used for centuries by
native Andean populations as aphrodisiac, energizer, and
enhancers of fertility and sexual function [38]. With the
advent of Internet, maca has become a common ingredient
of sexual enhancer products available worldwide.
3.2.2. Active Ingredients and Mechanism of Action. Maca
extracts have been shown to contain benzyl glucosino-
lates and polyphenols, (1R,3S)-1-methyl-1,2,3,4-tetrahydro-𝛽-
carboline-3-carboxylic acid (MTCA), and p-methoxybenzyl
isothiocyanate amongmany other chemicals [39].Themech-
anism of action of maca in altering sexual behaviour is
unknown.
3.2.3. Pharmacokinetics. No information could be found
related to the pharmacokinetics properties of Maca.
3.2.4. Efficacy. Zheng et al. reported increased sexual
behaviour in male rats and mice and decreased latency to
erection in testes-removed rats following oral administration
of lipid extracts ofmaca roots [40]. Cicero et al. demonstrated
that sexual behavioural activity as well as locomotor activity
was increased in rats treated with pulverised maca root orally
[41]. In a further study, the same group has demonstrated
that the hexanic extract of maca had more effect on sexual
behaviour of rats than the methanolic and chloroformic
extracts [42]. Lentz et al. measured ejaculatory andmounting
behaviour and postejaculatory intervals in rats treated with
maca orally for 30 days. They found that maca had only a
small effect on sexual behaviour and locomotor activity but
no effect on anxiety [43].
The studies with maca on human subjects were reviewed
in 2010 [44]. Four randomised clinical trials met the authors’
inclusion criteria: two trials suggested a significant positive
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Table 2: Subjective reports of forums’ users about sexual enhancers side effects.
Gingko
biloba
(i) Head rush
(ii) Anxiety
(iii) Feeling of blood flowing through skin/feeling blood warming
(iv) Tinnitus
http://www.drugs-forum.com/forum/showthread.php?t=77902
(i) Increased heart rate
(ii) Dizziness
(iii) Chest pain
(iv) Phosphenes
http://forum.lef.org/default.aspx?f=35&m=16405
Anxiety and nausea (Ginkgo tea consumption while assuming clomipramine)
http://www.socialanxietysupport.com/forum/f11/ginkgo-biloba-197737/
Maca
(i) Altered menstrual cycle (length modifications, anovulatory cycles)
(ii) Painful intestinal cramps
(iii) Severe gastritis
(iv) Increased blood pressure
(v) Moodiness
http://archive.tcoyf.com/forums/t/119232.aspx
(i) Increased heart rate
(ii) Insomnia
(iii) Depression/anxiety
(iv) Worse premenstrual syndrome symptoms
(v) Acne breakout
http://www.highonhealth.org/what-nobody-tells-you-about-maca-root-powder-dangers-and-side-effects/
Mood swings
http://babyandbump.momtastic.com/pregnancy-tests/419834-gallery-o-tests-1075.html#post9282851
Horny
goat weed
(i) Fever
(ii) Increased heart rate
(iii) Aggressiveness
(iv) Irritability
http://www.muscleandstrength.com/supplements/ingredients/horny-goat-weed.html#5
effect of maca on sexual dysfunction or sexual desire in
healthy postmenopausal women [45] or healthy adult men
[46], while the other trial failed to show any effects on
healthy cyclists [47]. A further trial assessed the effects
of maca in patients with erectile dysfunction using the
International Index of Erectile Function Questionnaire and
showed significant effects [48]. Lee et al. have reviewed the
literature to determine maca’s possible effects on menopausal
symptoms and confirmed the inadequacy of the present
data to clearly state efficacy and safety [49]. An overview
of systematic reviews on various complementary medicine
products for sexual dysfunction in elderly patients has found
that the evidence for maca was insufficient [50].
3.2.5. Safety. Piacente et al. (2002) have shown the
existence of 1R,3S-1-methyl-1,2,3,4-tetrahydro-𝛽-carboline-
3-carboxylic acid (MTCA) in the extracts of maca. MTCA
has been suggested to be an inhibitor of the monoamine
oxidase (MAO) enzyme and is a comutagenic or a precursor
to mutagenic compounds [51]. Because of these potential
mutagenic properties of MTCA, the French Agency for
Sanitary Security warned consumers of powdered maca root
about possible health risks from its ingestion [52]. These
findings have been disputed by others based on the
assumption that MTCA is deactivated during the boiling
process of the maca roots [53]. MTCA-like compounds
have also been suggested to be associated with craving
behaviour, which is common in addictions [51]. Side effects
subjectively reported by fora users were altered menstrual
cycles, moodiness, cramps, gastritis, and insomnia (see
Table 2).
3.3. Horny Goat Weed
3.3.1. Source and Preparations. Epimedium is a genus of plants
of the Berberidaceae family, including more than 50 species.
Among themost frequently used in sexual enhancer products
are Epimedium grandiflorum and Epimedium sagittatum.
Epimedium grandiflorum is commonly known as horny goat
weed named after the legendary discovery of its aphrodisiac
properties, attributed to a Chinese goat herder who noticed
an increased sexual activity in his herd after they ate the
plant’s leaves [54], and sold onlinewith various names includ-
ingViaXtreme, which also contains undeclared sildenafil [17].
3.3.2. Active Ingredients and Mechanism of Action. The active
ingredient of horny goat weed has been suggested to be
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icariin, a flavonol glycoside [55]. Icariin and its derivatives
have been suggested to increase NO synthesis in the penis
[56], inhibit PDE5 in cavernosal smoothmuscle [57–59], have
positive neurotrophic effect on nitrergic nerves [56], enhance
smooth muscle proliferation [60], and decrease advanced
glycation endproduct formation [60] andmimic endogenous
androgens [61]. Icariin has also been suggested to have anti-
inflammatory, antiosteoporotic, and neuroprotective proper-
ties [62–64].
3.3.3. Pharmacokinetics. Icariin has been shown to have low
oral bioavailability, poor absorption, and short plasma half-
life [65]. Because of these unfavourable pharmacokinetics
profiles, liposome encapsulated formulations of icariin are
being developed [66].
3.3.4. Efficacy. Although icariin has been shown to be effi-
cacious in treatment of erectile dysfunction in aged [67],
diabetic [68], and castrated [69] animal models, it has not
been tested in any randomised clinical trial.
3.3.5. Safety. No long-term toxicity study has been conducted
using horny goat weed (or icariin) in any animal species.
Partin and Pushkin have presented a case of a 66-year-old
man with a history of cardiovascular disease who, after two
weeks of consumption of herbal sexual enhancer containing
horny goat weed, was admitted to hospital with a new-
onset tachyarrhythmia and hypomanic symptoms (sexual
and verbal inappropriate behaviour, irritable mood, and
hyperverbal speech). The patient needed to undergo an
electric cardioversion and to be treated with a therapy based
on olanzapine and lorazepam [70]. Metz et al. reported a case
of a painful vasculitic rash in a 77-year-old man, who had
started a treatment with Ginkgo biloba and horny goat weed
tablets four days before. The man improved after three days
as an inpatient, with the suspension of the herbal supplement
[71].
3.3.6. Psychological Safety. As mentioned above, one case
has been reported with hypomanic symptoms combined
with tachyarrhythmia [70]. During the online monitoring
of discussion fora, several cases of aggressive behaviour and
irritability were noted (see Table 2).
3.4. Ginkgo biloba
3.4.1. Source and Preparations. Ginkgo biloba is a living fossil
tree, belonging to Ginkgoaceae family. Typically grown in
China, Ginkgo plants are tall, normally reaching 20–35m of
height, with fan-shaped leaves. The extracts obtained from
Ginkgo leaves contain flavonoid glycosides (e.g., myricetin
and quercetin) and terpenoids (e.g., ginkgolides and bilob-
alides) and have been used for centuries in traditional
Chinese medicine, particularly for memory enhancement
and blood flow improvement.
3.4.2. Active Ingredients and Mechanism of Action. The most
commonly used Ginkgo biloba extract is EGb761, which
contains flavonoid glycosides, mainly composed of kaemp-
ferol, quercetin glucorhamnoside esters, and terpenes of
ginkgolides and bilobalides. These ingredients have been
suggested to have the ability to inhibit MAO enzyme and
uptake of certain neurotransmitters such as noradrenaline
and serotonin in the central nervous system [72]. A recent
meta-analysis of 28 clinical studies with Ginkgo has found no
significant effect on cognitive function [73]. Ginkgo extracts
have been suggested to improve sexual function by improving
the blood flow to the brain as well as to the genital organs.
These extracts have also been suggested to increase NO
bioavailability, which may have positive impact on sexual
function [74].
3.4.3. Pharmacokinetics. Extracts of Ginkgo are a mixture
of substances with a wide variety of physical and chemical
properties and activities. A recent review on the pharma-
cokinetic properties of these substances concluded that the
available pharmacokinetic data are rare and more studies
need to be conducted [75]. It is generally accepted that
Ginkgo extract is well absorbed in humans, rats, and rabbits
after oral administration [75].
3.4.4. Efficacy. Ginkgo extracts have been tested as a treat-
ment for antidepressant-induced sexual dysfunction, which
is a common side effect in depressive disorder therapy,
especially when using selective serotonin reuptake inhibitors
(SSRIs). Despite the initial positive effect on sexual function
based on various case reports [76], two randomised placebo
controlled trials have found no significant benefit on sexual
function with Ginkgo extracts [77, 78]. Although Ginkgo
extracts have been suggested for the treatment of female sex-
ual arousal disorders [79], no placebo controlled randomised
trial has been reported.
3.4.5. Safety. A recent long-term study by National Tox-
icology Program has demonstrated that oral administra-
tion of Ginkgo extract caused cancer of thyroid gland and
liver, atrophy of the olfactory epithelium, nephropathy, and
mononuclear cell leukaemia in rats and mice [80]. One of
the major ingredients, quercetin, is a known mutagen [81].
In reviews of the efficacy and safety of Ginkgo extracts in
human subjects, no serious side effects were reported in
clinical trials and side effects were similar to those seen in
the placebo groups [82]. Ginkgo extract has been suggested
to affect platelet aggregation, whichmay not only be useful in
prevention of pathological events as thrombosis, butmay also
cause spontaneous bleeding in healthy individuals or patients
treated with anticoagulants such as warfarin and aspirin [83].
There have been case reports of subdural hematoma or cere-
bral haemorrhage with headache, confusion, blurred vision,
nausea, and vomiting afterGinkgo administration [84]. Some
Ginkgo extracts may contain 4󸀠-O-methylpyridoxine, which
is a neurotoxin also known as “ginkgotoxin.” Ginkgotoxin
poisoning is characterised by epileptic convulsions, vomiting,
unconsciousness, and irritability, which may be fatal if not
promptly treated [85].
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3.4.6. Psychological Safety. Ginkgo may interact with other
medications particularly those acting on the central ner-
vous system. It may decrease (alprazolam, citalopram, and
diazepam) or increase (clozapine, methadone, olanzapine,
and fluvoxamine) effects and side effects of such drugs; it may
also induce hypomanic symptoms when taken together with
St. John’s wort, fluoxetine, and melatonin [86]. Anxiety was
the most common psychological effect reported by Ginkgo
users at Internet discussion fora (see Table 2).
3.5. Other Substances. Velvet antler has been used in tradi-
tional Chinese medicine for centuries, mainly as an ener-
gizer and to treat joint pain, cardiovascular diseases, and
impotence. The name refers to the velvety skin covering
growing antlers of male elk, deer, and moose, which can be
removed with no harm for the animal. In western countries,
elks and deer are anesthetized with xylazine or lidocaine
before having velvet removed; this practice had determined
an ethical controversy among veterinarians, to find balance
between animal welfare and food safety (not being known
drugs’ withdrawal time for velvet) [87]. The most relevant
issue currently identified for elk or deer velvet antler con-
sumption is related to an infectious neurodegenerative prion
disease known as chronic wasting disease (CWS). The core
symptoms of this encephalopathy are notable weight loss and
behavioural abnormalities (e.g., progressive hyperexcitabil-
ity) [88]. Though currently interspecies transmission has not
been yet demonstrated, the presence of CWSprions in animal
muscle, fat, glands, and antler velvet may expose humans to
infection by handling or consumption of diseased cervids
products [89, 90]. No psychoactive properties have been yet
demonstrated for velvet antler.
Turnera diffusa, also known as “damiana,” is a small shrub
common in Mexico, Central and South America, and the
Caribbean. Turnera diffusa leaf is traditionally thought to be
stimulant, aphrodisiac, tonic, diuretic, laxative, and useful to
treat menstrual and pregnancy disorders [91]. Aphrodisiac
and psychoactive properties have been ascribed for centuries
to damiana. Its leaves are usually boiled to make an infusion
with the aim of intensifying sexual sensations; moreover,
when smoked, damiana leaves may produce similar effects
to marijuana [92]. It has recently been found in products
advertised on the Internet to increase sensuality, especially
among women [16], as legal and safer alternative to Cannabis
and sold as “mystical incenses” [93, 94]. These also often
contain synthetic cannabinoids such as JWH-18, JWH-73,
and HU210 that may cause severe intoxication and death
[95, 96].
Nymphaea caerulea is a lotus flower belonging to
Nymphaeaceae family. It is also known as “Blue Water Lily”
or “Egyptian Lotus” and it is sold as a powder named “Blue
Lotus.” The flower has been used by ancient Egyptians not
only to enhance sex drive and to improve sexual performance,
but also to stimulate blood flow and as an antiageing treat-
ment. It has also recreational potential when added to wine
or smoked, due to its psychoactive properties [97].The flower
may indeed induce both narcotic and euphoric effects and,
if taken in large amounts, may cause slightly hallucinogenic
symptoms [98].
Ptychopetalum olacoides (Muira puama), also called
“potency wood,” grows primarily in Brazil. Popular belief
claims that it can improve sexual function especially in old
men [7]. This herb may be found in plant markets or in
herbal formulations, usually sold to increase physical, mental,
and/or sexual performance. Few clinical studies have so far
examined the prosexual effects of Muira puama. Waynberg
reported in 1994 that 60% of men with low libido have
reported increased sexual desire and 50% of men with poor
erection have reported improved erectile function following
Muira puama administration [99]. Another study has shown
that Muira puama improved sexual desire, sexual fantasies,
and the ability to achieve orgasm in 65% of womenwith prior
sexual dysfunction [100].
3.5.1. Synthetic Substances. Among synthetic substances used
as sexual enhancers, well-known examples include MDPV
(methylenedioxypyrovalerone), known as “Ivory Wave,” 2C-
B, and mephedrone (4-methylmethcathinone), also called
with the nickname of “Miaow Miaow.” The aforementioned
substances have stimulating and aphrodisiac properties sim-
ilar to amphetamines and MDMA (“Ecstasy”). Because of
their partially synthetic and partially natural composition,
some sexual enhancer substances are defined ”mixed.” Lust
is a stimulant made up of Sida cordifolia extract. This
plant contains L-ephedrine, which is a natural amphetamine
acting on both central and peripheral nervous systems. The
effects of L-ephedrine are mainly linked to an expansion of
sexual perception [101]. Another component of Lust is saw
palmetto (Serenoa repens, Serenoa serrulata), another natural
aphrodisiac; the plant’s berries are used to increase muscular
power and libido. The last Lust component is L-arginine, an
amino acid believed to have positive effects on impotence and
infertility [102].
4. Discussion and Conclusions
The exponential increase in the use of unlicensed sexual
enhancing products, often characterized by the undeclared
presence of psychoactive agents, represents a serious chal-
lenge both from clinical and public health point of view,
despite their large and uncontrolled distribution on the
Internet, including e-commerce websites (Ebay, Amazon).
It has been estimated that approximately six million men
in the EU purchase these products from the Internet [103].
Possible reasons behind such a risky behaviour include (a)
the embarrassment to speak with a doctor, (b) the thought
that buying them online would be the fastest and cheapest
way to solve the problem, (c) curiosity, (d) peer-pressure,
and (e) the increase of sexual confidence and performance
[5].
In a performance-based society, the e-commerce of food
and herbal supplements sold for sexual enhancing purposes
is becoming a highly profitable market as a result of low-
cost manufacturing capacity in countries such as China and
India as well as the globalization of free trade and the Internet
as a platform for rapid distribution [94, 103, 104]. In this
context, unscrupulous manufacturers/retailers are exploiting
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the common belief that “natural” products are healthier
alternatives to pharmaceutical treatments and infiltrate unde-
clared harmful psychoactive substances in their products
[5]. This represents a growing public health threat, which is
putting the population at risk.The frequent occurrence of side
effects and the potential induction of symptoms of psychiatric
interest, such as mood elevation, anxiety, hallucinations, and
other psychotic symptoms, are issues that need to be clarified
and constantly monitored at the international level [105, 106].
The possible impact on subjects with psychiatric disorders,
usually at risk for sexual disjunctions and therefore possible
consumers, may be devastating.
Sexual function is closely related to the function of the
central nervous system; it is therefore not surprising that
psychological and psychiatric disorders are closely associated
with sexual dysfunction [107]. For example, depression can
be a cause or result of erectile dysfunction. Some of the
antidepressants can also cause sexual dysfunction. It is there-
fore essential that patients with sexual dysfunction either
of psychogenic or organic aetiology should avoid taking
such herbal products which may have adverse effects on
their mental state. Similarly, patients taking centrally acting
medications such as antidepressants or antipsychotics should
avoid using such products which may cause unwanted herb-
drug interactions and hence side effects, one of whichmay be
sexual dysfunction.
In addition, there is still a distinct paucity of evidence-
based and up-to-date information available for medical
professionals on the effects and risks associated with the
consumption of these products. In this sense, the use of
unstructured, free, and near real-time sources of information
such as Internet news and online reports is essential to
rapidly acquire and share knowledge and understanding of
the rapidly changing drug market and be better prepared to
face this new challenge globally.
A limitation of this study was that only publicly available
websites and similar sources were monitored. In order to
improve the coverage of the study, not only the websites
but also more private ways of communication (including
newsgroups, chat rooms, mailing lists, social networking, e-
newsletters, bulletin boards, and videos) were monitored.
Because some of the discussion fora have restricted access
to non-registered members, a comprehensive quantitative
analysis could not always be fully performed. A further
limitation may be that the present findings do rely mostly on
what is reported by users. We did not have any possibility to
ascertain whether the substance the online alleged drug users
were taking was only a sexual stimulant or a combination of
various products.
Considering the fact that only less than 1% of the side
effects are reported for herbal products, it is concerning to
find the variety of psychological symptoms disclosed by the
users in online discussion fora, which may only be a fraction
of the tip of an iceberg. In conclusion, the four substances,
yohimbine, maca, horny goat weed, and Ginkgo biloba,
commonly found in sexual enhancement products carry
potential safety risks particularly in psychological context.
The users, physicians, and regulators should be aware of these
risks.
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